Compare Medtronic PLC (MDT) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Xpeng Inc - ADR — how do they compare? Medtronic PLC trades at $88.79 (market cap $112.24B), while Xpeng Inc - ADR trades at $9.91 (market cap $9.16B). The key difference: Medtronic PLC is far larger — about 12.3× Xpeng Inc - ADR's market cap, and Medtronic PLC pays a 3.28% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Xpeng Inc - ADR for 80 Days on average.
| MDT | XPEV | |
|---|---|---|
Market Cap | $112.24B | $9.16B |
Volume | 105,663,236 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $28.07 |
52-Week Low | $73.75 | $9.25 |
Typical Hold Time | 63 Days | 80 Days |
Enterprise Value | $131.58B | $11.09B |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $88.48, up 3.47% today, with a bullish analyst consensus and a $97.80 price target. The stock shows strong fundamentals with revenue growth to $33.54B in 2025 and a net income margin of 13.93%. Recent earnings beats and a 49-year dividend growth streak highlight operational strength, though technical indicators signal a near-term bearish trend with key support at $87.
MDT presents a compelling long-term investment with stable profitability and dividend reliability, but faces risks from debt increases and competitive pressures. Upside potential exists if the company maintains earnings momentum and executes on growth initiatives, while volatility may persist due to market sentiment shifts.
XPeng (XPEV) trades at $9.90, up 3.34% with a bearish technical signal despite recent delivery growth. The company shows improving fundamentals with revenue surging to $76.72B in 2025 and narrowing losses, though it remains unprofitable with negative margins. Recent news highlights expansion into robotics and global vehicle launches, while analyst consensus remains bullish with a $17.55 price target representing 77% upside potential.
XPeng presents a high-risk, high-reward opportunity with strong revenue growth and technological innovation offset by persistent profitability challenges. The stock's current discount to analyst targets offers potential upside, but investors face risks from competitive pressures, execution challenges in new business lines, and ongoing losses that could pressure the balance sheet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
